influenza
viru
iav
caus
season
influenza
epidem
influenza
pandem
result
seriou
threat
public
health
socioeconom
impact
drug
belong
two
categori
use
prophylaxi
treatment
iav
infect
hemagglutinin
ha
envelop
glycoprotein
iav
play
critic
role
viral
bind
fusion
entri
therefor
ha
attract
target
develop
antiiav
drug
block
entri
step
iav
infect
review
recent
progress
studi
conform
chang
ha
viral
fusion
process
develop
habas
iav
entri
inhibitor
may
provid
new
choic
control
futur
influenza
pandem
main
influenza
virus
iav
caus
acut
respiratori
diseas
human
bird
mammal
repres
one
major
threat
public
health
wild
bird
reservoir
influenza
virus
avian
strain
adapt
human
host
attain
humantohuman
transmiss
capabl
acquir
mutat
unexpect
human
adapt
influenza
subtyp
strain
rather
current
circul
influenza
virus
may
caus
pandem
flu
pandem
spanish
flu
asian
flu
hong
kong
flu
swine
flu
symbol
devast
public
health
socioeconom
impact
pandem
flu
keep
us
alert
outbreak
addit
season
flu
respons
death
per
year
type
iav
infect
patient
hong
kong
caus
death
potenti
seriou
threat
human
health
near
futur
high
mortal
potenti
humantohuman
transmiss
influenza
virus
mutat
frequent
segment
rna
genom
make
almost
imposs
produc
time
suffici
effect
vaccin
prevent
potenti
oseltamivirresist
influenza
virus
epidem
outbreak
therefor
way
use
antiinfluenza
agent
treatment
prevent
begin
pandem
outbreak
virul
influenza
strain
give
time
develop
widespread
dissemin
effect
vaccin
two
class
antiinfluenza
drug
avail
clinic
target
ion
channel
neuraminidas
na
express
viru
envelop
respect
adamantan
block
ion
channel
form
protein
critic
releas
viral
ribonucleoprotein
complex
vrnp
cytoplasm
although
ion
channel
inhibitor
effect
influenza
viru
infect
report
caus
central
nervou
system
cn
side
effect
also
current
circul
iav
strain
mostli
resist
adamantan
thu
adamantan
recommend
gener
uncontrol
use
two
neuraminidas
inhibitor
oseltamivir
zanamivir
approv
treatment
prevent
acut
uncompl
flu
caus
influenza
b
neuraminidas
inhibitor
interfer
enzymat
activ
na
protein
critic
effici
releas
newli
synthes
virus
infect
cell
howev
resist
viru
strain
constantli
emerg
especi
oseltamivir
differ
oral
administr
oseltamivir
zanamivir
inhal
due
low
bioavail
make
limit
use
drug
new
na
inhibitor
peramivir
author
emerg
treatment
certain
hospit
patient
known
suspect
influenza
seem
quit
press
seek
new
antiinfluenza
medic
life
cycl
influenza
viru
well
understood
allow
valid
sever
therapeut
target
among
hemagglutinin
ha
one
appeal
one
till
subtyp
ha
identifi
subdivid
clade
group
figur
malleabl
natur
ha
impos
great
difficulti
conduct
ration
drug
design
furthermor
varieti
ha
may
even
strengthen
antigen
drift
antigen
shift
describ
function
structur
studi
lead
discoveri
ha
new
antiinfluenza
target
also
structur
inform
facilit
ration
design
new
iav
entri
inhibitor
target
ha
hemagglutinin
encod
fourth
negativestrand
rna
segment
influenza
viral
genom
rna
segment
encod
residu
posttransl
glycosyl
trimer
chaperon
endoplasm
reticulum
er
infect
cell
subsequ
undergo
extraor
intracellular
cleavag
process
critic
step
matur
influenza
viru
progeni
acquir
infect
ha
subtyp
circul
influenza
virus
human
conserv
cleavag
site
sole
basic
amino
acid
residu
specifi
sequenc
qexr
recogn
extracellular
tissuerestrict
trypsinlik
proteas
howev
highli
pathogen
avian
influenza
hpai
virus
multibas
cleavag
site
rxrkr
ha
recogn
ubiquit
express
intracellular
proteas
facilit
system
viru
spread
greater
pathogen
proper
proteolyt
cleavag
glycosyl
disulfid
bound
subunit
residu
residu
form
fusogen
homotrim
whose
structur
resembl
mushroom
plant
viral
envelop
figur
globular
head
mushroom
mainli
construct
subdomain
includ
receptor
bind
subdomain
vestigi
esteras
subdomain
antigen
epitop
receptor
bind
subdomain
recogn
link
termin
sialic
acid
sa
membran
glycoprotein
receptor
host
cell
therefor
prime
viruscel
adsorpt
endocytosi
viru
entri
stem
mushroom
mainli
compos
inner
trimer
ectodomain
subunit
embrac
nand
ctermin
segment
first
residu
ntermin
function
fusion
peptid
fp
fp
accommod
hydrophob
pocket
form
partial
fusion
domain
acidif
induc
rearrang
prerequisit
exposur
releas
fp
subdomain
inner
pocket
subsequ
low
phtrigger
reconform
result
fusion
viral
envelop
endosom
membran
figur
fusion
allow
releas
viral
ribonucleocapsid
vrnp
cytoplasm
infect
cell
lead
complet
entri
step
figur
scheme
phinduc
conform
chang
prefus
postfus
state
approxim
locat
residu
mark
figur
adapt
paper
publish
j
virol
globular
head
crown
expos
outmost
surfac
environ
play
incipi
central
role
virushost
interact
bind
host
receptor
recogn
host
antibodi
evad
host
immun
system
mutat
glycosyl
specif
epitop
meanwhil
electrostat
interact
posit
charg
inner
surfac
site
neg
charg
site
stabil
trimer
ha
neutral
ph
fusion
dissoci
trimer
spike
necessari
complet
spring
unload
close
involv
critic
step
viral
entri
probabl
contain
sever
critic
site
interact
host
cell
also
potenti
medicin
target
develop
antivir
drug
receptor
bind
site
ha
resembl
shallow
pocket
whose
structur
compos
motif
locat
surfac
globular
head
residu
termin
sa
cell
membran
glycoprotein
natur
receptor
hamedi
viral
adsorpt
sit
top
two
aromat
residu
bottom
bind
pocket
accordingli
theoret
investig
molecular
dynam
md
simul
reveal
bottom
bind
pocket
form
hydrogen
bond
link
termin
sa
variou
ha
subtyp
besid
bind
site
pocket
conserv
amino
acid
edg
top
pocket
locat
front
edg
left
side
pocket
respect
receptor
bind
site
ha
mainli
consist
residu
bottom
residu
highli
conserv
among
subtyp
ha
avian
influenza
virus
ha
bind
predominantli
link
termin
sa
therefor
bare
overstep
host
speci
barrier
infect
human
link
termin
sa
upper
respiratori
tract
trachea
word
acquir
infect
human
avian
influenza
virus
acquir
adequ
bind
avid
link
termin
sa
accumul
genet
drift
andor
reassort
theoret
investig
md
simul
found
residu
form
direct
watermedi
hydrogen
bond
link
termin
sa
howev
bind
link
termin
sa
instead
instead
form
direct
watermedi
hydrogen
bond
addit
residu
still
form
hydrogen
bond
penultim
galactos
receptor
rather
link
termin
sa
likewis
residu
form
direct
watermedi
hydrogen
bond
link
termin
sa
compar
interact
link
termin
sa
residu
fail
form
interact
link
termin
sa
associ
report
sever
mutat
correspond
site
result
alter
bind
specif
sa
therefor
may
even
creat
strain
avian
influenza
viru
transmiss
mammal
ferret
recent
research
indic
two
mutat
avian
influenza
viru
chang
receptor
bind
prefer
avian
human
sa
result
viru
capabl
respiratori
transmiss
human
maintain
lethal
replic
howev
two
mutat
hpai
virus
caus
switch
bind
specif
though
substitut
posit
could
chang
receptorbind
prefer
ha
sa
strikingli
imai
et
al
identifi
four
mutat
allow
highli
pathogen
viru
transmit
respiratori
droplet
ferret
base
fact
sa
ha
receptor
sabas
inhibitor
exploit
potenti
antiha
agent
one
influenza
virion
usual
contain
ha
trimer
surfac
monoval
sa
analog
figur
would
unabl
compet
highli
multival
interact
virus
host
cell
therefor
inhibitor
bival
tetraval
even
polyval
sialosid
afford
enhanc
inhibitori
activ
monoval
ligand
polyval
sialosid
show
high
potenc
vitro
current
acknowledg
recognit
sa
indispens
influenza
virus
gain
effici
transmiss
human
therefor
multival
could
effect
protect
newli
emerg
pandem
influenza
viru
strain
otherwis
possibl
design
transitionst
bind
analogu
inhibit
receptorbind
viral
adsorpt
altern
sa
analog
teruhiko
et
al
identifi
peptid
figur
bind
receptorbind
site
multipl
serial
select
phagedisplay
random
peptid
librari
dock
simul
suggest
peptid
mimic
structur
bind
abil
sa
exampl
nsteroyl
peptid
c
h
coarlprtmvnh
c
h
could
inhibit
infect
influenza
viru
ic
valu
respect
peptid
eb
found
exhibit
broadspectrum
antivir
activ
influenza
virus
vitro
vivo
even
administ
postinfect
analysi
demonstr
eb
peptid
specif
bind
viral
ha
protein
entri
blocker
smaller
peptid
cndfrsktc
similar
inhibitori
mechan
eb
also
deriv
result
indic
habind
peptid
promis
candid
antivir
drug
well
antiha
antibodi
ha
iav
often
undergo
nlink
glycosyl
nlg
sever
site
nlg
globular
head
ha
known
modul
antigen
fusion
activ
virul
receptorbind
specif
viru
suscept
neuraminidas
inhibitor
immun
evas
iav
interf
glycosyl
site
surfact
protein
spd
play
import
role
innat
defens
iav
pathogen
spd
collectin
includ
mannos
bind
lectin
mbl
conglutinin
inhibit
iav
bind
glycan
viral
bind
collectin
high
mannos
oligosaccharid
hemagglutinin
ha
appear
import
viral
neutral
inspir
report
antivir
activ
glycosyl
inhibitor
nonactin
nbutyldeoxynojirimycin
nbdnj
may
possibl
achiev
antiinfluenza
activ
appropri
glycosyl
inhibit
strategi
clear
exampl
antibodi
target
glycan
ha
yet
report
suggest
may
fertil
area
futur
discoveri
effort
analys
ha
sequenc
variat
natur
influenza
viru
isol
caus
epidem
studi
viru
mutat
induc
antiinfluenza
monoclon
antibodi
antigen
site
identifi
ha
design
sa
residu
near
receptor
bind
site
sb
residu
overlap
receptor
bind
site
near
top
surfac
globular
head
ha
residu
residu
subunit
interfac
stem
region
ha
cb
residu
near
base
globular
head
antigen
site
ha
base
studi
ha
sequenc
variat
antigen
variat
viru
four
antigen
site
suggest
site
residu
near
receptor
bind
site
site
b
overlap
receptor
bind
site
site
c
residu
disulfid
bound
site
residu
overlay
receptor
bind
site
subunit
interfac
bind
antigen
epitop
antibodi
play
central
role
recognit
elimin
invad
virus
therefor
iav
evolv
lowfidel
polymeras
result
high
mutat
rate
divers
glycosyl
antigen
site
escap
recognit
neutral
antibodi
due
viral
antigen
shift
drift
influenza
antibodi
vaccin
often
expir
short
period
therefor
lead
edg
isol
discov
novel
broadli
neutral
monoclon
antibodi
bnmab
recogn
highli
conserv
site
conserv
ha
stem
domain
elicit
crossreact
antibodi
epitop
globular
head
typic
elicit
strainspecif
respons
hypervari
region
howev
receptor
bind
site
conserv
sinc
mutat
interf
receptor
bind
like
impair
viral
adsorpt
infect
base
fact
antigen
site
overlap
receptor
bind
site
site
exploit
natur
occur
antibodi
human
exampl
neutral
also
virus
show
hemagglutin
inhibit
activ
compet
antibodi
thought
bind
stem
region
compet
antibodi
recogn
site
b
especi
residu
strikingli
anoth
bnmab
achiev
nanomolar
bind
minim
footprint
tini
sa
bind
site
mainli
insert
singl
heavychain
complimentarili
determin
region
loop
similarli
anoth
bnmab
also
insert
loop
receptor
bind
pocket
moreov
receptorbind
bnmab
isol
b
cell
suggest
receptorbind
site
antibodi
found
natur
potenti
induc
vaccin
strategi
though
review
talk
mainli
antivir
target
viru
ha
develop
still
catch
nerv
hosttarget
drug
candid
clinic
develop
influenza
field
kda
recombin
fusion
protein
compos
sialidas
catalyt
domain
deriv
actinomyc
viscosu
fuse
mucos
cell
surfaceanchor
domain
cleav
sa
host
mucos
cell
surfac
inactiv
host
cell
receptor
viral
adsorpt
therebi
consequ
block
viral
entri
respiratori
epitheli
cell
cleav
present
potent
inhibitori
effect
panel
laboratori
strain
clinic
isol
influenza
b
virus
includ
hpai
strain
vitro
ec
valu
rang
nm
recent
research
reveal
also
activ
oseltamivirresisit
strain
besid
broadspectrum
antivir
activ
treatment
may
also
protect
airway
epithelium
inflamm
denud
underli
mechan
prevent
secondari
bacteri
infect
find
highlight
potenti
broad
spectrum
activ
novel
drugresist
influenza
viru
strain
contrast
cleav
receptor
sa
host
cell
membran
shield
receptor
sa
cell
membran
anoth
strategi
interfer
bind
event
viru
host
cell
alkyl
two
peptid
use
nsterol
peptid
deriv
respect
alkyl
group
two
peptid
abl
promot
format
peptid
assembl
ensur
multival
bind
sacontain
receptor
respect
could
inhibit
infect
influenza
viru
ic
valu
subunit
link
viru
capsul
membran
own
highli
conserv
sequenc
conduct
irrevers
fusion
virus
cell
endosom
membran
low
ph
condit
make
viru
genet
materi
releas
cell
construct
two
differ
length
trend
revers
parallel
b
ring
form
two
spiral
connect
fusion
peptid
locat
ntermin
twenti
residu
figur
earli
peptid
deriv
hiv
envelop
protein
found
strong
activ
hiv
capabl
prevent
hiv
membran
fusion
among
polypeptid
becom
first
hiv
entri
inhibitor
target
trimer
structur
approv
us
fda
kind
new
type
antivir
drug
suitabl
hiv
patient
drug
resist
discoveri
hiv
peptid
enlighten
scientist
studi
type
envelop
viru
entri
inhibitor
respiratori
syncyti
viru
rsv
measl
viru
ebola
viru
viral
enceph
sever
acut
respiratori
distress
syndrom
coronaviru
sarscov
influenza
viru
also
belong
type
envelop
scientist
tri
find
similar
polypeptid
like
capabl
fight
iav
far
success
report
mayb
result
obstacl
process
develop
antiinfluenza
polypeptid
unlik
hiv
membran
fusion
influenza
viru
happen
endosom
environ
acid
ph
polypeptid
deriv
subunit
pass
cell
membran
get
endosom
becom
unstabl
acid
condit
peptid
effect
prevent
membran
fusion
mediat
hemagglutinin
chemic
method
call
hydrocarbon
stapl
appli
design
spiral
polypeptid
cell
membran
penetr
studi
hiv
found
peptid
activ
fight
hiv
method
may
applic
search
antivir
polypeptid
haemagglutinin
target
anoth
strategi
find
small
molecular
compound
cell
membran
penetr
oral
bioavail
compound
interact
ha
stop
membran
fusion
figur
howev
screen
antiinfluenza
compound
target
high
throughput
necessari
confirm
whether
three
polym
possess
target
point
suitabl
combin
fusion
fusion
transit
state
target
caviti
hiv
highli
conserv
thu
easi
induc
resist
compound
interact
caviti
resist
mutat
segment
may
lead
loss
hiv
virul
studi
antivir
compound
advis
devot
effort
conserv
target
point
accord
hemagglutinin
conserv
target
hole
exist
spiralscrew
part
process
membran
fusion
mediat
ha
endocytosi
endosom
ha
happen
irrevers
restructur
drop
ph
small
molecular
compound
prevent
low
ph
trigger
ha
restructur
benzen
anthraquinon
hydroquinon
compound
promis
benzodiazepin
deriv
tbhq
restrain
viru
infect
concentr
pressur
tbhq
mutat
lead
resist
appear
subunit
show
tbhq
appli
subunit
cocrystal
tbhq
ha
also
analyt
tbhq
combin
subunit
stabil
trimer
structur
neutral
condit
thu
make
disabl
restructur
fusion
low
ph
three
residu
own
compet
ioniz
also
capabl
interact
tbhq
monom
adjac
monom
tbhq
stop
infect
influenza
viru
rather
subunit
hemagglutinin
form
salt
bridg
subunit
haemagglutinin
tend
form
salt
bridg
therefor
exist
subunit
combin
tbhq
molecular
dock
screen
two
compound
found
better
antivir
activ
russia
approv
antiinfluenza
drug
arbidol
act
increas
influenza
viru
ha
stabil
prevent
low
phinduc
ha
transit
fusogen
state
howev
potent
broadspectrum
antivir
drug
wellknown
russia
china
recent
studi
exploit
characterist
arbidolresist
mutant
influenza
viru
confirm
inhibitori
mechan
scientist
wyethayerst
found
three
compound
nreplac
piperidin
inhibit
activ
avian
influenza
reach
micromol
level
test
resist
viru
strain
found
ha
protein
sequenc
mutat
happen
amino
acid
locat
ha
trimer
stem
area
near
fusion
peptid
part
computeraid
drug
design
scientist
reveal
abl
bind
part
caviti
may
prevent
ha
restructur
trigger
low
ph
involv
two
pathway
enhanc
stabil
residu
around
caviti
prevent
amino
acid
proton
caus
acid
damag
interact
forc
residu
stop
fusion
peptid
move
make
disabl
form
structur
necessari
fusion
analog
potent
inhibit
influenza
viru
infect
found
also
potent
inhibit
influenza
viru
target
hemagglutinin
caviti
receptor
bind
least
includ
mutat
studi
show
also
critic
inhibitori
activ
critic
residu
cluster
stem
region
ha
trimer
extens
comput
simul
includ
md
simul
molecular
mechan
gener
born
surfac
area
mmgbsa
calcul
carri
uncov
detail
molecular
mechan
found
recognit
bind
ha
proce
process
induc
fit
wherebi
bind
pocket
form
interact
occup
pocket
stabil
neutral
ph
structur
hemagglutinin
thu
inhibit
conform
rearrang
requir
membran
fusion
recent
optim
structur
found
trifluoromethyl
benzamid
segment
critic
viru
activ
substitut
pyrrolidin
ring
thiophen
ring
increas
activ
one
fold
make
compound
attract
candid
develop
oral
avail
antiinfluenza
drug
research
japan
found
antiinfluenza
membran
fusion
inhibitor
stachyflin
deriv
separ
ferment
broth
medium
botryoid
ear
mould
stachyflin
effect
prevent
infect
subtyp
subtyp
avian
influenza
valu
micromol
level
stachyflin
stop
fusion
viru
membran
interf
ha
restructur
trigger
low
ph
analyz
ha
gene
sequenc
stachyflin
resist
strain
two
point
mutat
found
locat
subunit
suggest
stachyflin
bind
site
subunit
team
also
design
synthes
stachyflin
deriv
acetylstachyflin
better
bioavail
antivir
activ
report
progress
type
antivir
drug
scientist
bristol
myer
squibb
found
anoth
new
kind
fusion
inhibitor
inhibit
influenza
viru
studi
found
combin
ha
prevent
low
ph
trigger
ha
restructur
ha
gene
sequenc
analysi
drugresist
strain
found
mutat
site
locat
ntermin
subunit
show
compound
prevent
ha
mediat
membran
fusion
interact
ntermin
subunit
eli
lilli
research
found
strong
inhibit
toward
earli
stage
viru
replic
analyz
ha
gene
sequenc
drugresist
strain
found
resist
mutat
exist
subunit
adjac
interfac
posit
near
fusion
peptid
ph
membran
fusion
occur
drugresist
strain
unit
higher
wild
type
suggest
stabil
structur
ha
neutral
state
prevent
low
phtrigger
ha
restructur
tang
et
al
report
seri
benzenesulfonamid
deriv
recent
potent
antiinfluenza
activ
target
ha
compound
modifi
salicylamidebas
ha
inhibitor
cyclohexylmethyl
benzamid
lead
compound
analogu
effect
prevent
infect
influenza
strain
valu
nm
respect
vivo
data
suggest
protect
effect
mice
lethal
challeng
influenza
viru
mechan
action
studi
indic
compound
inhibit
viru
membran
fusion
host
endosom
membran
bind
ha
stabil
prefus
ha
structur
compound
also
significantli
improv
metabol
stabil
could
develop
first
gener
oral
bioavail
ha
inhibitor
chloroquin
inexpens
wide
avail
antimalaria
drug
recent
vitro
assay
suggest
chloroquin
may
util
treatment
sever
viral
infect
includ
influenza
vigerust
et
al
test
vivo
effect
ferret
model
result
show
clinic
sign
viral
replic
nose
ferret
alter
treatment
recent
finish
randomis
doubleblind
placebo
control
trial
show
chloroquin
prevent
infect
influenza
case
chloroquin
group
found
catch
laboratoryconfirm
influenza
infect
although
gener
well
toler
healthi
commun
popul
dampen
enthusiasm
potenti
util
drug
human
influenza
found
small
molecul
potent
inhibit
group
iav
group
iav
vanderlinden
et
al
report
new
seri
n
carboxamid
inhibitor
show
mark
antivir
activ
group
influenza
virus
lead
compound
select
index
compound
specif
activ
subtyp
subtyp
among
structur
protein
influenza
virus
hemagglutinin
play
import
role
viral
bind
receptor
viru
entri
membran
fusion
antibodi
specif
ha
shown
inhibit
andor
neutral
viru
infect
vaccin
host
antiha
monoclon
antibodi
mab
regard
one
import
passiv
therapeut
treatment
influenza
compani
theraclon
intend
screen
human
donor
broadli
neutral
crossreact
human
antibodi
hemagglutinin
current
flu
vaccin
mainli
provok
antibodi
target
head
region
ha
part
protein
chang
easili
therefor
mab
recogn
conserv
efficaci
epitop
may
broadli
neutral
homolog
heterolog
strain
differ
clade
iav
infect
prevent
format
escap
mutant
although
antibodi
induc
virusneutr
activ
monoclon
antibodi
mab
specif
fusion
peptid
abl
inhibit
ha
fusion
activ
reduc
viru
replic
vitro
also
vivo
antibodi
first
isol
person
vaccin
season
flu
viru
neutral
test
show
exhibit
broad
neutral
activ
antigen
divers
group
influenza
virus
recent
test
shown
also
combat
novel
viru
caus
pandem
moreov
strongli
outperform
oseltamivir
influenza
prevent
treatment
preclin
studi
research
reveal
crucel
mab
bind
part
h
surfac
protein
chang
viru
mutateswhich
great
eas
h
surfac
protein
crucial
replic
influenza
viru
site
bound
antibodi
viru
fuse
membran
insid
host
cell
therefor
reproduc
mab
neutral
viru
stabil
prefus
state
strongli
inhibit
conform
chang
ha
fusogen
ph
neutral
like
due
glycosyl
residu
posit
also
undesir
conserv
epitop
recogn
particularli
expos
intact
viru
epitop
identifi
acceler
design
implement
improv
vaccin
elicit
antibodi
well
antibodybas
therapi
treatment
influenza
besid
new
broadli
neutral
mab
also
bind
common
conserv
region
ha
monoclon
antibodi
target
highli
conserv
viral
epitop
might
offer
altern
protect
paradigm
mab
igg
monoclon
antibodi
provid
broadli
effici
protect
treatment
influenza
viru
bind
novel
conform
epitop
nterminu
protein
epitop
recogn
conserv
known
influenza
strain
includ
avian
swine
strain
also
demonstr
potent
protect
vivo
soiv
influenza
strain
clinic
trial
undergo
show
safeti
effect
besid
broadli
neutral
crossreact
human
antibodi
hemagglutinin
screen
human
donor
date
sever
candid
identifi
bind
broadli
neutral
group
well
subtyp
group
influenza
strain
avian
flu
viru
ha
crystal
structur
avian
influenza
viru
ha
crystal
structur
unfold
peopl
get
better
understand
haemagglutinin
crystal
structur
show
ha
trimer
form
monom
ha
hydrolyz
subunit
host
proteas
two
hydrolyz
subunit
connect
disulfid
figur
structur
ha
precursor
structur
hydrolysi
alik
six
residu
ctermin
residu
ntermin
subunit
distribut
fuse
especi
residu
cover
polar
amino
acid
expos
liquid
environ
make
ha
vulner
hydrogen
ion
excit
structur
chang
hydrolysi
necessari
step
avian
influenza
viru
contagi
therefor
molecul
prevent
hydrolyz
subunit
possess
abil
fight
viral
infect
serin
proteas
inhibitor
antiproteas
peptid
constitut
amino
acid
eaminocapro
acid
nafamostat
pulmonari
surfact
kind
surfac
activ
lipoprotein
complex
mucou
proteas
inhibitor
reduc
hydrolysi
infect
influenza
virus
cell
model
anim
model
figur
kind
inject
treat
symptom
bleed
cow
pancrea
inhibitor
proteas
peptid
trasylol
bayer
appli
clinic
practic
howev
withdrawn
clinic
applic
studi
find
drug
could
increas
mortal
fda
approv
pulmonari
surfact
exosurf
curosurf
infasurf
survanta
enhanc
lung
complianc
prevent
babi
respiratori
distress
syndrom
quasi
peptid
inhibitor
decrvkrcmk
resist
alkalin
amino
acid
proteas
inhibit
replic
avian
flu
high
pathogen
recent
research
report
hydrolyz
subtyp
therefor
natur
inhibitor
human
bodi
serv
lead
compound
develop
antivir
drug
target
haemagglutinin
found
quasi
peptid
inhibitor
also
restrain
insulin
proteas
plasmin
may
mechan
action
inhibitori
peptid
influenza
viru
infect
addit
inhibitor
natur
molecul
also
possess
good
inhibitori
activ
influenza
viru
infect
figur
exampl
catechin
isol
green
tea
like
egcg
found
exhibit
mild
antiinfluenza
effect
modif
catechin
deriv
set
better
inhibitor
better
antiinfluenza
drug
candid
catechin
deriv
possess
broad
spectrum
antiinfluenza
activ
besid
curcumin
wide
use
spice
color
agent
indian
food
prove
good
viru
entri
inhibitor
target
ha
ec
valu
modif
curcumin
may
produc
seri
novel
ha
target
inhibitor
anoth
kind
small
molecul
inhibitor
deriv
andrographolid
like
show
signific
activ
avian
influenza
human
influenza
virus
vitro
capabl
direct
interf
viral
ha
block
viral
bind
cellular
receptor
demonstr
inhibitori
activ
viral
adsorpt
red
blood
cell
li
group
china
report
first
three
small
saponin
molecul
inhibit
ha
three
compound
potent
inhibit
entri
viru
aviet
ic
low
level
modif
reveal
reduct
disaccharid
chain
would
abolish
inhibitori
activ
inhibitor
therefor
antiinfluenza
agent
natur
product
especi
tradit
chines
medicin
tcm
promis
lead
compound
lead
compound
tcm
extens
intens
review
xu
et
al
ha
major
surfac
protein
iav
mediat
viral
bind
membran
fusion
viral
entri
determin
crystal
structur
provid
import
inform
understand
phinduc
conform
chang
ha
prefus
intermedi
postfus
state
develop
antiinfluenza
drug
although
seri
antiinfluenza
drug
target
na
ion
channel
current
avail
emerg
drugresist
virus
rais
great
concern
ineffect
newli
emerg
iav
hpai
virus
thu
essenti
develop
novel
antiiav
drug
new
target
number
proteinbas
small
molecul
antiiav
agent
shown
interfer
hamedi
membran
fusion
target
receptor
bind
block
cleavag
inhibit
low
phmediat
conform
chang
ha
seem
easi
find
design
small
compound
target
bind
event
influenza
viru
conform
chang
mediat
membran
fusion
promis
target
develop
antiinfluenza
drug
novel
influenza
viru
entri
inhibitor
may
provid
select
combin
therapi
na
inhibitor
ion
channel
blocker
treat
prevent
influenza
viru
infect
potenti
pandem
outbreak
